A multiple ascending dose study of AKB-4924 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2018
At a glance
- Drugs AKB 4924 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Aerpio Pharmaceuticals
- 25 Jun 2018 According to an Aerpio Pharmaceuticals media release, this trial was initiated in May 2018.
- 25 Jun 2018 According to an Aerpio Pharmaceuticals media release, status changed from planning to recruiting.
- 22 May 2018 New trial record